drugset / Trial / NCT02178098

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

NCT02178098

Phase 2 Completed 143 enrolled Esperion Therapeutics, Inc. Medpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.

Timeline

Start
2014-06-16
Primary completion
2015-05-22
Completion
2015-05-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 180 mg Oral